Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist

M. Ichinose, N. Nakajima, T. Takahashi, H. Yamauchi, H. Inoue, T. Takishima

Research output: Contribution to journalArticlepeer-review

173 Citations (Scopus)


Axon reflex mechanisms may be involved in the pathogenesis of asthma, but there has been no direct evidence that endogenous tachykinins cause bronchoconstriction in asthmatic subjects. We have studied the effect of a tachykinin receptor antagonist (FK-224) on bronchoconstriction induced by inhalation of bradykinin in asthmatic patients. In a double-blind, placebo-controlled, crossover trial, ten subjects with stable asthma were given FK-224 (4 mg) or placebo by inhalation 20 min before challenge with bradykinin (0-1250 μg/ml, five breaths of each concentration) given with 5 min intervals. Bradykinin caused dose-dependent bronchoconstriction in all subjects. FK-224 significantly opposed the bronchoconstrictor effect; the geometric mean of the cumulative concentration required to elicit a 35% fall in specific airway conductance was 5·3 μg/ml after placebo and 40 μg/ml after FK-224 (p<0·001). Inhalation of bradykinin caused coughing in three subjects, which was inhibited by FK-224 in all three. Antagonism of the tachykinin receptor by FK-224 greatly inhibited both bronchoconstriction and coughing induced by bradykinin in asthmatic patients, suggesting that tachykinin release from the airway sensory nerves is involved in responses to bradykinin. Tachykinin receptor antagonists may be useful in the treatment of asthma.

Original languageEnglish
Pages (from-to)1248-1251
Number of pages4
JournalThe Lancet
Issue number8830
Publication statusPublished - 1992 Nov 21

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist'. Together they form a unique fingerprint.

Cite this